Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update

Citius Oncology, Inc. (NASDAQ:CTOR) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 983,877 shares, a growth of 51.2% from the December 15th total of 650,544 shares. Based on an average daily trading volume, of 727,864 shares, the short-interest ratio is presently 1.4 days. Currently, 1.2% of the shares of the company are sold short. Currently, 1.2% of the shares of the company are sold short. Based on an average daily trading volume, of 727,864 shares, the short-interest ratio is presently 1.4 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new stake in Citius Oncology in the third quarter valued at $36,000. Bank of America Corp DE increased its holdings in shares of Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after purchasing an additional 8,411 shares in the last quarter. Arkadios Wealth Advisors purchased a new position in shares of Citius Oncology in the 2nd quarter valued at about $51,000. IFP Advisors Inc lifted its stake in shares of Citius Oncology by 49.5% in the third quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock valued at $67,000 after purchasing an additional 11,000 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Citius Oncology by 179.0% in the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after purchasing an additional 36,758 shares during the period. Institutional investors and hedge funds own 70.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on CTOR shares. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Oncology in a research report on Monday, December 22nd. Citigroup upgraded Citius Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, September 23rd. Finally, Maxim Group upgraded Citius Oncology from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a research note on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $6.00.

Citius Oncology Trading Down 2.8%

NASDAQ CTOR opened at $1.05 on Friday. The company has a quick ratio of 0.11, a current ratio of 0.56 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $89.04 million, a P/E ratio of -3.09 and a beta of 3.09. Citius Oncology has a 52-week low of $0.55 and a 52-week high of $6.19. The firm has a 50-day moving average price of $1.18 and a 200 day moving average price of $1.76.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings data on Tuesday, December 23rd. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06).

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.